CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 274 enrolled
Drug / intervention
Cholecalciferol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02881957
NCT02881957Phase 3Completed

Randomized Clinical Trial of Hypovitaminosis D Treatment in the Neurocritical Care Unit

University of Utah·interventional·Posted Aug 29, 2016·Updated Jun 15, 2022

In Brief

A Phase 3 clinical trial evaluating Cholecalciferol and Placebo for Craniocerebral Trauma and 9 related conditions. Completed, enrolled 274 participants across 1 site.

Detailed Summary

Vitamin D has been shown to impact prognosis in a variety of retrospective and randomized clinical trials within an intensive care unit (ICU) environment. Despite these findings, there have been no studies examining the impact of hypovitaminosis D in specialized neurocritical care units (NCCU). Given the often significant differences in the management of patients in NCCU and more generalized intensive care units there is a need for further inquiries into the impact of low vitamin D levels in this specific environment. This study proposes a randomized, double-blinded, placebo-controlled, single center evaluation of vitamin D supplementation in the emergent NCCU patient population. The primary outcome will involve length-of-stay for emergent neurocritical care patients. Various secondary outcomes, including in-hospital mortality, ICU length-of-stay, Glasgow Outcome Score on discharge, complications and quality-of-life metrics. Patients will be followed for 6 months post-discharge.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 29, 2016
Enrollment StartOct 10, 2016
Primary CompletionOct 10, 2018
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 9.8 years ago

Interventions

Cholecalciferoldrug

Placeboother

Oral syrup placebo